Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:06:27.821Z.
Calculation as of: 2026-10-06T17:06:27.821Z.
Quote observation: 2026-10-06T17:04:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 719625f658538d7511a1815ebd8f3969041d2dee7d9c9a78aa46ea1e1d2f6eab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$321.56M
Price/FCF Ratio
71.40
TTM Avg
796.59
3Y Avg
1526.97
5Y Avg
1526.97
Market Cap
$329.18M
Price/FCF Ratio
N/A
TTM Avg
114347.68
3Y Avg
114347.68
5Y Avg
114347.68
Market Cap
$303.90M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.02M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $323.89M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $323.78M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.00M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.56M | 71.40 | 796.59 | 1526.97 | 1526.97 |
| Agenus Inc. (AGEN)vs › | $329.18M | N/A | 114347.68 | 114347.68 | 114347.68 |
| C4 Therapeutics, Inc. (CCCC)vs › | $315.67M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $303.90M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.57M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.23M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
